Benzinga | Jul 15, 2020 09:46AM EDT

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $177

Morgan Stanley maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $181 to $177.